NYSE — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
www.adctherapeutics.comADC Therapeutics is demonstrating strong potential with its novel exatecan-based ADCs, which could expand treatment options for various cancers.
ADC Therapeutics will present updated data from the LOTIS-7 trial during a poster session on June 14, 2025, at the EHA2025 Congress in Milan, Italy. The trial evaluates the efficacy of ZYNLONTA in combination with glofitamab for patients with relapsed/refractory DLBCL, showing promising results with an overall response rate of 95.5%.
clinical readoutADC Therapeutics will present data on marginal zone lymphoma at the International Conference on Malignant Lymphoma (ICML) from June 17-21, 2025, in Lugano, Switzerland. The presentation will include findings from a phase 2 study of loncastuximab in patients with relapsed/refractory marginal zone lymphoma, highlighting its potential efficacy in this patient population.
clinical readoutInitial data from the LOTIS-7 trial of ZYNLONTA plus glofitamab showed a 94% best ORR and 72% CR rate, with a data update expected in Q2 2025.
clinical readoutEnrollment in the LOTIS-5 Phase 3 trial of ZYNLONTA plus rituximab is complete, with a data update anticipated in late 2025 after PFS events.
clinical readoutADC Therapeutics anticipates sharing topline results of the LOTIS-5 trial's primary endpoint analysis by the end of 2025, which may support a supplemental BLA submission in Q1 2026.
clinical readoutADC Therapeutics plans to submit a supplemental Biologics License Application (BLA) for ZYNLONTA to the FDA in Q1 2026, following the LOTIS-5 trial results.
fda decision